NCT05856760Phase 2Completed

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

Study sponsor: Travere Therapeutics, Inc. · TVTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-10-14Actual
Enrollment · participants48Actual
Source updated2025-11-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview